A Phase 1, Open-label Study With Two Independent Parts: Collecting Samples for Metabolites in Safety Testing Analysis of Zibotentan After Repeated Administration (Part 1); and a Randomised, Cross-over, Three Period, Three-treatment, Single Dose Study to Assess the Relative Bioavailability of Different Formulations of Zibotentan and Dapagliflozin (Part 2) in Healthy Adult Participants
Latest Information Update: 24 Nov 2021
At a glance
- Drugs Dapagliflozin (Primary) ; Zibotentan (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 22 Nov 2021 Status changed from active, no longer recruiting to completed.
- 07 Oct 2021 Planned End Date changed from 6 Oct 2021 to 12 Oct 2021.
- 07 Oct 2021 Planned primary completion date changed from 6 Oct 2021 to 12 Oct 2021.